Literature DB >> 1761065

Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus.

M Busch Sørensen1, H Sjøstrand, H Sengeløv, M Tiefenthal Thrane, J Juul Holst, J Lyngsøe.   

Abstract

The effect of a sustained-release verapamil preparation on glucose metabolism was investigated in 10 patients with non-insulin dependent diabetes mellitus. In a single blind cross-over study verapamil 240 mg b.d. for 1 week lowered fasting plasma glucose from a mean value of 11.6 mmol/l to 10.3 mmol.l-1, and the fasting glucose appearance rate was decreased from 1.5 to 1.2 mmol.min-1. The decrease in fasting plasma glucose and glucose appearance rate was not related to the steady state plasma concentration of verapamil, nor-verapamil and the metabolites D.617 and D.620. After oral glucose administration a tendency to lower plasma glucose values was found after verapamil administration. Plasma insulin, C-peptide, total and C-terminal glucagon were not significantly different in the placebo and the verapamil studies, neither in the fasting state nor after glucose. It is concluded that brief verapamil treatment decreases fasting plasma glucose and glucose turn-over in non-insulin dependent diabetics, possibly by inhibition of gluconeogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761065     DOI: 10.1007/bf00626359

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Effect of oral verapamil on glibenclamide stimulated insulin secretion.

Authors:  C G Semple; C Omile; K D Buchanan; G H Beastall; K R Paterson
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

2.  Calcium antagonists and hormone release. VI. Effects of a calcium antagonist (verapamil) on the biphasic insulin release in vivo.

Authors:  A Barbarino; L De Marinis; A Mancini; F Calabrò; M Massari; C D'Amico; P Sambo; A Tofani; G Folli
Journal:  Diabetes Res       Date:  1988-05

3.  Influence of verapamil on human glucose tolerance.

Authors:  S Röjdmark; D E Andersson
Journal:  Am J Cardiol       Date:  1986-02-26       Impact factor: 2.778

Review 4.  Calcium antagonists and hormone release.

Authors:  J A Millar; A D Struthers
Journal:  Clin Sci (Lond)       Date:  1984-03       Impact factor: 6.124

5.  Do antihypertensive drugs precipitate diabetes?

Authors:  I Whitcroft
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-26

6.  Effect of Verapamil on pancreatic glucagon release from the isolated, perfused canine pancreas.

Authors:  K Hermansen; J Iversen
Journal:  Scand J Clin Lab Invest       Date:  1977-04       Impact factor: 1.713

7.  Influence of verapamil on glucose tolerance.

Authors:  S Röjdmark; D E Andersson
Journal:  Acta Med Scand Suppl       Date:  1984

8.  Sustained-release and instant-release verapamil in treatment of angina pectoris.

Authors:  C M Jespersen; N A Klitgaard; H Nielsen; J F Hansen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Effects of nonselective and beta-1-selective blockade on glucose metabolism and hormone responses during insulin-induced hypoglycemia in normal man.

Authors:  U B Lauridsen; N J Christensen; J Lyngsøe
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

10.  Influence of oral verapamil on glucoregulatory hormones in man.

Authors:  H Shamoon; P Baylor; D Kambosos; S Charlap; S Plawes; W H Frishman
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

View more
  2 in total

1.  Verapamil and beta cell function in adults with recent-onset type 1 diabetes.

Authors:  Fernando Ovalle; Tiffany Grimes; Guanlan Xu; Anish J Patel; Truman B Grayson; Lance A Thielen; Peng Li; Anath Shalev
Journal:  Nat Med       Date:  2018-07-09       Impact factor: 53.440

2.  Integrating systems biology sources illuminates drug action.

Authors:  A Gottlieb; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2014-02-27       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.